Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, reported today financial results for the first half of the financial year 2022.
“The current year has been very successful from our business perspective and underlines the steadily increasing traction that Marinomed is gaining. The recent deals are important steps to foster our geographical expansion strategy. We will work closely with our partners Procter & Gamble (P&G) in the U.S.A, with Hanmi in South Korea and with M8 in Latin America to support their interactions with the respective regulatory authorities for market approval,” said Dr. Andreas Grassauer, Marinomed’s CEO. “Business development and visibility are top priorities on our agenda. We are working to advance our strategy for building a Marinosolv- and Carragelose-based Rx segment. For our first target indications, we are now planning the specifics of preclinical and / or further clinical development. We look forward to taking the next steps in our scientific development and further intensifying our partnering efforts. In the first half year of 2022, we have also been successful with our new Solv4U business, an offering for external partners to take advantage of our Marinosolv technology for the solubilization of active pharmaceutical ingredients. We have already completed a number of proof-of-concept studies and are setting up several, more extensive, follow-on projects.”
The full press release is available as download here: